Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Harvoni Most Prescribed Drug at Acute Hospitals in October-December
April 27, 2016
-
BUSINESS Novartis Looks to Harness Big Data for Indication Expansions: Global Medical Chief
April 26, 2016
-
REGULATORY Making PMDA World’s Most Trusted Regulatory Authority through “Regulatory Innovation”: Chief Executive
April 25, 2016
-
BUSINESS Kaketsuken Continues to Suspend Production as Huge Damages Found
April 22, 2016
-
BUSINESS Around 140 Clinical Trials of Nucleic Acid Drugs Underway Worldwide, with Cancer, Neuropathy, and Myopathy as Main Targets
April 22, 2016
-
BUSINESS Japan’s 1st PCSK9 Inhibitor Hits Market; MHLW Issues Notification to Prevent Hasty Use
April 21, 2016
-
ACADEMIA AMED Study Team Drafting First Guidelines for Diagnosis and Treatment of Post-Stroke Epilepsy
April 21, 2016
-
ACADEMIA 17 Japanese Medical Societies Jointly Recommend HPV Vaccines
April 20, 2016
-
REGULATORY Sales Reps Top Source of Drug Safety Information for Both Clinics and Pharmacies: PMDA Survey
April 19, 2016
-
BUSINESS Wholesalers Say Drug Distributions in Quake-Hit Kumamoto More or Less Stable
April 19, 2016
-
BUSINESS Kaketsuken Halts Operations on April 18-20 after Quake
April 18, 2016
-
REGULATORY Promoting Use of Patient Registries Important in Building Clinical Innovation Network: Health Policy Bureau Chief
April 18, 2016
-
REGULATORY Expedited Review Systems Now in Place in 3 Major Markets, but How Are They Different?
April 15, 2016
-
REGULATORY Indication-Based Front-Loaded Re-Pricing, Coverage Limits Emerge for Pricey Meds: Chuikyo
April 14, 2016
-
REGULATORY Chuikyo OKs Repatha for NHI Price Listing on April 20, Peak Sales Projected at 49 Billion Yen
April 13, 2016
-
BUSINESS Ono Fires Back to 1.75 Trillion Yen Guesstimate, Puts Opdivo Sales at 126 Billion Yen
April 12, 2016
-
ORGANIZATION EFPIA Japan Chief to Call for “Real Dialogue” at Today’s Public-Private Policy Confab
April 12, 2016
-
REGULATORY With Eyes on Pricey Meds, Cost-Shaving Debate Unabated Despite Likely Tax Hike Delay
April 11, 2016
-
BUSINESS Kaketsuken in Talks to Transfer Vaccine Biz to Astellas
April 8, 2016
-
ORGANIZATION Front-Loaded Price Cuts Necessary for Drugs Like Opdivo: JMA’s Nakagawa
April 7, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…